Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ALEXANDRIA REAL ESTATE EQUITIES, INC.ARE · Entity 419 | Director | January 15, 2025 | January 17, 2025 |
| HANGER, INC.HGR · Entity 14115 | Director | May 19, 2017 | May 23, 2017 |
| Korro Bio, Inc.FREQ · Entity 6388 | Director | August 17, 2022 | August 19, 2022 |
| STERIS plcSTE · Entity 3228 | Director | August 10, 2026 | August 12, 2026 |
| UFP TECHNOLOGIES INCUFPT · Entity 4409 | Director | August 13, 2026 | August 17, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ALEXANDRIA REAL ESTATE EQUITIES, INC.
Report date January 15, 2025 · Filed January 17, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 5,742 |
Reported balance
After 2025-01-15 transaction · row 1
1 source rowRow 1 · 2025-01-15 · Grant · Acquired 2,032 · Balance 5,742 |
HANGER, INC.
Report date May 19, 2017 · Filed May 23, 2017
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 109,072 |
Reported balance
After 2017-05-19 transaction · row 1
1 source rowRow 1 · 2017-05-19 · Grant · Acquired 10,964 · Balance 109,072 F1: Consists of shares of restricted stock granted under the Company's 2016 Omnibus Incentive Plan (the "Plan"), which vest 100% on May 19, 2018, subject to certain provisions of the Plan. |
Filing footnotes · ownership attribution and instrument terms
F1: Consists of shares of restricted stock granted under the Company's 2016 Omnibus Incentive Plan (the "Plan"), which vest 100% on May 19, 2018, subject to certain provisions of the Plan.
Korro Bio, Inc.
Report date August 17, 2022 · Filed August 19, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $2.14 · Expires 2030-09-22 | Direct | 29,693 |
Reported balance
After 2022-08-17 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2022-08-17 · Grant · Acquired 29,693 · Balance 29,693 F2: The transaction reported herein reflects a one-time stock option repricing that became effective on August 17, 2022 and is being reported in this manner solely to comply with the technical reporting requirements under Section 16(a) of the Securities Exchange Act of 1934, as amended. There have been no other changes to the terms of these options. F1: The option vests and becomes exercisable in equal monthly installments over a three year period commencing on October 23, 2020, and will be fully vested and exercisable on September 23, 2023. |
| Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $20.37 · Expires 2030-09-22 | Direct | 0 |
Reported balance
After 2022-08-17 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2022-08-17 · Disposition to issuer · Disposed 29,693 · Balance 0 F2: The transaction reported herein reflects a one-time stock option repricing that became effective on August 17, 2022 and is being reported in this manner solely to comply with the technical reporting requirements under Section 16(a) of the Securities Exchange Act of 1934, as amended. There have been no other changes to the terms of these options. F1: The option vests and becomes exercisable in equal monthly installments over a three year period commencing on October 23, 2020, and will be fully vested and exercisable on September 23, 2023. |
| Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $2.14 · Expires 2031-06-16 | Direct | 14,846 |
Reported balance
After 2022-08-17 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2022-08-17 · Grant · Acquired 14,846 · Balance 14,846 F2: The transaction reported herein reflects a one-time stock option repricing that became effective on August 17, 2022 and is being reported in this manner solely to comply with the technical reporting requirements under Section 16(a) of the Securities Exchange Act of 1934, as amended. There have been no other changes to the terms of these options. F3: The option vested in full on the earlier of June 17, 2022 or the day immediately prior to the company's 2022 annual meeting of shareholders. |
| Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $10.14 · Expires 2031-06-16 | Direct | 0 |
Reported balance
After 2022-08-17 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2022-08-17 · Disposition to issuer · Disposed 14,846 · Balance 0 F2: The transaction reported herein reflects a one-time stock option repricing that became effective on August 17, 2022 and is being reported in this manner solely to comply with the technical reporting requirements under Section 16(a) of the Securities Exchange Act of 1934, as amended. There have been no other changes to the terms of these options. F4: The option vests in full on the earlier of June 17, 2022 or the day immediately prior to the company's 2022 annual meeting of shareholders. |
Filing footnotes · ownership attribution and instrument terms
F1: The option vests and becomes exercisable in equal monthly installments over a three year period commencing on October 23, 2020, and will be fully vested and exercisable on September 23, 2023.
F2: The transaction reported herein reflects a one-time stock option repricing that became effective on August 17, 2022 and is being reported in this manner solely to comply with the technical reporting requirements under Section 16(a) of the Securities Exchange Act of 1934, as amended. There have been no other changes to the terms of these options.
F3: The option vested in full on the earlier of June 17, 2022 or the day immediately prior to the company's 2022 annual meeting of shareholders.
F4: The option vests in full on the earlier of June 17, 2022 or the day immediately prior to the company's 2022 annual meeting of shareholders.
STERIS plc
Report date August 10, 2026 · Filed August 12, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Director Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $238.91 · Expires 2036-08-10 | Direct | 1,506 |
Reported balance
After 2026-08-10 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-08-10 · Grant · Acquired 1,506 · Balance 1,506 F1: These nonqualified stock options are fully vested and are exercisable immediately. |
| Career Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 8,640 |
Reported balance
After 2026-08-10 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-08-10 · Grant · Acquired 512 · Balance 8,640 F2: Each Career Restricted Stock Unit represents the right to receive one STERIS ordinary share six months after the cessation of the Director's Board service. F3: These Career Restricted Stock Units are fully vested immediately. They will be settled in STERIS ordinary shares six months after the cessation of the Director's Board service. |
Filing footnotes · ownership attribution and instrument terms
F1: These nonqualified stock options are fully vested and are exercisable immediately.
F2: Each Career Restricted Stock Unit represents the right to receive one STERIS ordinary share six months after the cessation of the Director's Board service.
F3: These Career Restricted Stock Units are fully vested immediately. They will be settled in STERIS ordinary shares six months after the cessation of the Director's Board service.
UFP TECHNOLOGIES INC
Report date August 13, 2026 · Filed August 17, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common Stock, $.01 Par ValueSEC Table I · non-derivative | Direct | 4,476 |
Reported balance
After 2026-08-13 transaction · row 1
1 source rowRow 1 · 2026-08-13 · Sale · Disposed 1,000 · Balance 4,476 |
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
STERIS plc
Report date March 28, 2019 · Filed March 28, 2019
Section 16 reporting ended · disclosed 2019-03-28. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Ordinary Shares, 10 pence par valueSEC Table I · non-derivative | IndirectSee Footnote Below. | 0 |
Reported balance
After 2019-03-28 transaction · row 1
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 1 · 2019-03-28 · Disposition to issuer · Disposed 8,663 · Balance 0 F1: These ordinary shares, which were previously reported as directly owned, have been transferred to the Cynthia L. Feldman Revocable Trust, with Ms. Feldman and her husband as Trustees. F2: Represents ordinary shares of STERIS plc, a public limited company organized under the laws of England and Wales ("Old STERIS"), cancelled pursuant to a court-approved scheme of arrangement under English law (the "Scheme"). In connection with the Scheme, the reporting person received ordinary shares of STERIS plc, a public limited company organized under the laws of Ireland ("STERIS"), in an amount equal to the number of the reporting person's cancelled Old STERIS shares. The reporting person's STERIS shares will be subject to terms and conditions, including restrictions, substantially identical to those that were applicable to the Old STERIS shares. Following the completion of the Scheme, STERIS became the ultimate holding company of Old STERIS. |
| Director Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $64.05 · Expires 2025-08-31 | Direct | 0 |
Reported balance
After 2019-03-28 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2019-03-28 · Disposition to issuer · Disposed 4,110 · Balance 0 F3: This option is fully vested. This option was assumed by STERIS under the Scheme and converted to an option to purchase 4,110 ordinary shares of STERIS for $64.05 per share, subject to the same terms and conditions that were applicable to the original Old STERIS option. |
| Director Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $71.40 · Expires 2026-08-10 | Direct | 0 |
Reported balance
After 2019-03-28 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2019-03-28 · Disposition to issuer · Disposed 3,781 · Balance 0 F4: This option is fully vested. This option was assumed by STERIS under the Scheme and converted to an option to purchase 3,781 ordinary shares of STERIS for $71.40 per share, subject to the same terms and conditions that were applicable to the original Old STERIS option. |
| Director Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $86.23 · Expires 2027-08-09 | Direct | 0 |
Reported balance
After 2019-03-28 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2019-03-28 · Disposition to issuer · Disposed 4,058 · Balance 0 F5: This option is fully vested. This option was assumed by STERIS under the Scheme and converted to an option to purchase 4,058 ordinary shares of STERIS for $86.23 per share, subject to the same terms and conditions that were applicable to the original Old STERIS option. |
| Director Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $114.74 · Expires 2028-08-09 | Direct | 0 |
Reported balance
After 2019-03-28 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2019-03-28 · Disposition to issuer · Disposed 3,495 · Balance 0 F6: This option is fully vested. This option was assumed by STERIS under the Scheme and converted to an option to purchase 3,495 ordinary shares of STERIS for $114.74 per share, subject to the same terms and conditions that were applicable to the original Old STERIS option. |
| Career Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2019-03-28 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2019-03-28 · Disposition to issuer · Disposed 5,449 · Balance 0 F7: These career restricted stock units were assumed by STERIS pursuant to the Scheme and converted to career restricted stock units of STERIS representing the right to receive 5,449 STERIS ordinary shares. These career restricted stock units are fully vested and will be settled in STERIS ordinary shares six months after the cessation of the reporting person's board service, subject to the terms and conditions of the award agreement. |
Filing footnotes · ownership attribution and instrument terms
F1: These ordinary shares, which were previously reported as directly owned, have been transferred to the Cynthia L. Feldman Revocable Trust, with Ms. Feldman and her husband as Trustees.
F2: Represents ordinary shares of STERIS plc, a public limited company organized under the laws of England and Wales ("Old STERIS"), cancelled pursuant to a court-approved scheme of arrangement under English law (the "Scheme"). In connection with the Scheme, the reporting person received ordinary shares of STERIS plc, a public limited company organized under the laws of Ireland ("STERIS"), in an amount equal to the number of the reporting person's cancelled Old STERIS shares. The reporting person's STERIS shares will be subject to terms and conditions, including restrictions, substantially identical to those that were applicable to the Old STERIS shares. Following the completion of the Scheme, STERIS became the ultimate holding company of Old STERIS.
F3: This option is fully vested. This option was assumed by STERIS under the Scheme and converted to an option to purchase 4,110 ordinary shares of STERIS for $64.05 per share, subject to the same terms and conditions that were applicable to the original Old STERIS option.
F4: This option is fully vested. This option was assumed by STERIS under the Scheme and converted to an option to purchase 3,781 ordinary shares of STERIS for $71.40 per share, subject to the same terms and conditions that were applicable to the original Old STERIS option.
F5: This option is fully vested. This option was assumed by STERIS under the Scheme and converted to an option to purchase 4,058 ordinary shares of STERIS for $86.23 per share, subject to the same terms and conditions that were applicable to the original Old STERIS option.
F6: This option is fully vested. This option was assumed by STERIS under the Scheme and converted to an option to purchase 3,495 ordinary shares of STERIS for $114.74 per share, subject to the same terms and conditions that were applicable to the original Old STERIS option.
F7: These career restricted stock units were assumed by STERIS pursuant to the Scheme and converted to career restricted stock units of STERIS representing the right to receive 5,449 STERIS ordinary shares. These career restricted stock units are fully vested and will be settled in STERIS ordinary shares six months after the cessation of the reporting person's board service, subject to the terms and conditions of the award agreement.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 28, 2019 Filed Mar 28, 2019 13:50 UTC | STERIS plc STE · Entity 158792 | Disposition to issuerDirector Stock Option (right to buy) · Derivative | 4,110 | Not disclosed Strike: $64.05 | Not disclosed |
DisclosureSEC source: 0001209191-19-021559 · doc4.xml · derivative · entry 2 FELDMANN CYNTHIA L · CIK 0001264554 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 4,110 shares Expires 2025-08-31 F3 · price: This option is fully vested. This option was assumed by STERIS under the Scheme and converted to an option to purchase 4,110 ordinary shares of STERIS for $64.05 per share, subject to the same terms and conditions that were applicable to the original Old STERIS option. F3 · derivative.exercise_date: This option is fully vested. This option was assumed by STERIS under the Scheme and converted to an option to purchase 4,110 ordinary shares of STERIS for $64.05 per share, subject to the same terms and conditions that were applicable to the original Old STERIS option. Read SEC document |
| March 28, 2019 Filed Mar 28, 2019 13:50 UTC | STERIS plc STE · Entity 158792 | Disposition to issuerOrdinary Shares, 10 pence par value | 8,663 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-19-021559 · doc4.xml · nonDerivative · entry 1 FELDMANN CYNTHIA L · CIK 0001264554 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Below. Disclosed balance after: 0 F1 · shares: These ordinary shares, which were previously reported as directly owned, have been transferred to the Cynthia L. Feldman Revocable Trust, with Ms. Feldman and her husband as Trustees. F2 · price: Represents ordinary shares of STERIS plc, a public limited company organized under the laws of England and Wales ("Old STERIS"), cancelled pursuant to a court-approved scheme of arrangement under English law (the "Scheme"). In connection with the Scheme, the reporting person received ordinary shares of STERIS plc, a public limited company organized under the laws of Ireland ("STERIS"), in an amount equal to the number of the reporting person's cancelled Old STERIS shares. The reporting person's STERIS shares will be subject to terms and conditions, including restrictions, substantially identical to those that were applicable to the Old STERIS shares. Following the completion of the Scheme, STERIS became the ultimate holding company of Old STERIS. F1 · ownership.nature: These ordinary shares, which were previously reported as directly owned, have been transferred to the Cynthia L. Feldman Revocable Trust, with Ms. Feldman and her husband as Trustees. Read SEC document |
| February 20, 2019 Filed Feb 21, 2019 21:41 UTC | STERIS plc STE · Entity 158792 | Exercise / conversionDirector Stock Option (right to buy) · Derivative | 2,037 | $0.00 Strike: $51.53 | $0.00 |
DisclosureSEC source: 0001209191-19-012069 · doc4.xml · derivative · entry 3 FELDMANN CYNTHIA L · CIK 0001264554 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 2,037 shares Expires 2024-08-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: This option to purchase 2,037 STERIS plc ordinary shares, which is fully vested, was received in conjunction with the "Combination" of STERIS Corporation and Synergy Health, Ltd. in exchange for an option to purchase 2,037 STERIS Corporation common shares for $51.53 per share, subject to the same terms and conditions as the original STERIS Corporation stock option. Read SEC document |
| February 20, 2019 Filed Feb 21, 2019 21:41 UTC | STERIS plc STE · Entity 158792 | SaleOrdinary Shares, 10 pence par value | 2,037 | $122.51 | $249,552.87 |
DisclosureSEC source: 0001209191-19-012069 · doc4.xml · nonDerivative · entry 2 FELDMANN CYNTHIA L · CIK 0001264554 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,663 F1 · price: Price reflects a weighted average sale price for multiple transactions ranging from $122.49 to $122.53 per share, inclusive. The Reporting Person undertakes to provide, upon request by the SEC Staff, the Issuer or a security holder of the Issuer, full information regarding the number of shares sold at each separate price Read SEC document |
| February 20, 2019 Filed Feb 21, 2019 21:41 UTC | STERIS plc STE · Entity 158792 | Exercise / conversionOrdinary Shares, 10 pence par value | 2,037 | $51.53 | $104,966.61 |
DisclosureSEC source: 0001209191-19-012069 · doc4.xml · nonDerivative · entry 1 FELDMANN CYNTHIA L · CIK 0001264554 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,700 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 09, 2018 Filed Aug 10, 2018 20:20 UTC | STERIS plc STE · Entity 158792 | GrantCareer Restricted Stock Units · Derivative | 108 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-046222 · doc4.xml · derivative · entry 4 FELDMANN CYNTHIA L · CIK 0001264554 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,449 Underlying: Ordinary Shares · 108 shares Expires not disclosed F3 · derivative.exercise_price: Each Career Restricted Stock Unit represents the right to receive one STERIS ordinary share six months after the cessation of the Director's Board service. F4 · derivative.exercise_date: These Career Restricted Stock Units are fully vested immediately. They will be settled in STERIS ordinary shares six months after the cessation of the Director's Board service. F4 · derivative.expiration_date: These Career Restricted Stock Units are fully vested immediately. They will be settled in STERIS ordinary shares six months after the cessation of the Director's Board service. Read SEC document |
| August 09, 2018 Filed Aug 10, 2018 20:20 UTC | STERIS plc STE · Entity 158792 | GrantDirector Stock Option (right to buy) · Derivative | 3,495 | $0.00 Strike: $114.74 | $0.00 |
DisclosureSEC source: 0001209191-18-046222 · doc4.xml · derivative · entry 3 FELDMANN CYNTHIA L · CIK 0001264554 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,495 Underlying: Ordinary Shares · 3,495 shares Expires 2028-08-09 F2 · derivative.exercise_date: These nonqualified stock options are fully vested and are exercisable immediately. Read SEC document |
| August 09, 2018 Filed Aug 10, 2018 20:20 UTC | STERIS plc STE · Entity 158792 | Tax withholdingOrdinary Shares, 10 pence par value | 95 | $114.74 | $10,900.30 |
DisclosureSEC source: 0001209191-18-046222 · doc4.xml · nonDerivative · entry 2 FELDMANN CYNTHIA L · CIK 0001264554 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,663 F1 · shares: Represents the number of ordinary shares withheld to satisfy taxes. Read SEC document |
| August 09, 2018 Filed Aug 10, 2018 20:20 UTC | STERIS plc STE · Entity 158792 | GrantOrdinary Shares, 10 pence par value | 762 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-046222 · doc4.xml · nonDerivative · entry 1 FELDMANN CYNTHIA L · CIK 0001264554 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,758 Read SEC document |
| June 06, 2018 Filed Jun 7, 2018 20:25 UTC | UFP TECHNOLOGIES INC UFPT · Entity 4409 | GrantStock Option (Right to Buy) · Derivative | 1,724 | $0.00 Strike: $31.20 | $0.00 |
DisclosureSEC source: 0001739481-18-000031 · edgar.xml · derivative · entry 2 FELDMANN CYNTHIA L · CIK 0001264554 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,724 Underlying: Common Stock, $.01 Par Value · 1,724 shares Expires 2028-06-06 Read SEC document |
| June 06, 2018 Filed Jun 7, 2018 20:25 UTC | UFP TECHNOLOGIES INC UFPT · Entity 4409 | GrantCommon Stock, $.01 Par Value | 561 | $0.00 | $0.00 |
DisclosureSEC source: 0001739481-18-000031 · edgar.xml · nonDerivative · entry 1 FELDMANN CYNTHIA L · CIK 0001264554 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,208 F1 · shares: Represents shares issued under the issuer's 2009 Non-Employee Director Stock Incentive Plan Read SEC document |
| February 26, 2018 Filed Feb 27, 2018 21:24 UTC | STERIS plc STE · Entity 158792 | Exercise / conversionDirector Stock Option (right to buy) · Derivative | 3,218 | $0.00 Strike: $32.36 | $0.00 |
DisclosureSEC source: 0001209191-18-013909 · doc4.xml · derivative · entry 3 FELDMANN CYNTHIA L · CIK 0001264554 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 3,218 shares Expires 2022-08-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: This option to purchase 3,218 STERIS plc ordinary shares, which is fully vested, was received in conjunction with the "Combination" of STERIS Corporation and Synergy Health, Ltd. in exchange for an option to purchase 3,218 STERIS Corporation common shares for $32.36 per share, subject to the same terms and conditions as the original STERIS Corporation stock option. Read SEC document |
| February 26, 2018 Filed Feb 27, 2018 21:24 UTC | STERIS plc STE · Entity 158792 | SaleOrdinary Shares, 10 pence par value | 3,218 | $91.35 | $293,964.30 |
DisclosureSEC source: 0001209191-18-013909 · doc4.xml · nonDerivative · entry 2 FELDMANN CYNTHIA L · CIK 0001264554 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,996 F1 · price: Price reflects a weighted average sale price for multiple transactions ranging from $91.09 to $91.61 per share, inclusive. The Reporting Person undertakes to provide, upon request by the SEC Staff, the Issuer or a security holder of the Issuer, full information regarding the number of shares sold at each separate price Read SEC document |
| February 26, 2018 Filed Feb 27, 2018 21:24 UTC | STERIS plc STE · Entity 158792 | Exercise / conversionOrdinary Shares, 10 pence par value | 3,218 | $32.36 | $104,134.48 |
DisclosureSEC source: 0001209191-18-013909 · doc4.xml · nonDerivative · entry 1 FELDMANN CYNTHIA L · CIK 0001264554 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,214 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 09, 2017 Filed Aug 11, 2017 20:26 UTC | STERIS plc STE · Entity 158792 | GrantCareer Restricted Stock Units · Derivative | 231 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-048598 · doc4.xml · derivative · entry 4 FELDMANN CYNTHIA L · CIK 0001264554 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,341 Underlying: Ordinary Shares · 231 shares Expires not disclosed F2 · derivative.exercise_price: Each Career Restricted Stock Unit represents the right to receive one STERIS ordinary share six months after the cessation of the Director's Board service. F3 · derivative.exercise_date: These Career Restricted Stock Units are fully vested immediately. They will be settled in STERIS ordinary shares six months after the cessation of the Director's Board service. F3 · derivative.expiration_date: These Career Restricted Stock Units are fully vested immediately. They will be settled in STERIS ordinary shares six months after the cessation of the Director's Board service. Read SEC document |
| August 09, 2017 Filed Aug 11, 2017 20:26 UTC | STERIS plc STE · Entity 158792 | GrantDirector Stock Option (right to buy) · Derivative | 4,058 | $0.00 Strike: $86.23 | $0.00 |
DisclosureSEC source: 0001209191-17-048598 · doc4.xml · derivative · entry 3 FELDMANN CYNTHIA L · CIK 0001264554 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,058 Underlying: Ordinary Shares · 4,058 shares Expires 2027-08-09 F1 · derivative.exercise_date: These nonqualified stock options are fully vested and are exercisable immediately. Read SEC document |
| August 09, 2017 Filed Aug 11, 2017 20:26 UTC | STERIS plc STE · Entity 158792 | Tax withholdingOrdinary Shares, 0.10 Nominal Value | 123 | $86.23 | $10,606.29 |
DisclosureSEC source: 0001209191-17-048598 · doc4.xml · nonDerivative · entry 2 FELDMANN CYNTHIA L · CIK 0001264554 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,996 Read SEC document |
| August 09, 2017 Filed Aug 11, 2017 20:26 UTC | STERIS plc STE · Entity 158792 | GrantOrdinary Shares, 0.10 Nominal Value | 782 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-048598 · doc4.xml · nonDerivative · entry 1 FELDMANN CYNTHIA L · CIK 0001264554 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,119 Read SEC document |
| June 06, 2017 Filed Jun 8, 2017 18:07 UTC | UFP TECHNOLOGIES INC UFPT · Entity 4409 | GrantStock Option (Right to Buy) · Derivative | 2,056 | $0.00 Strike: $27.05 | $0.00 |
DisclosureSEC source: 0001240679-17-000028 · edgar.xml · derivative · entry 2 FELDMANN CYNTHIA L · CIK 0001264554 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,056 Underlying: Common Stock, $.01 Par Value · 2,056 shares Expires 2027-06-06 Read SEC document |
| June 06, 2017 Filed Jun 8, 2017 18:07 UTC | UFP TECHNOLOGIES INC UFPT · Entity 4409 | GrantCommon Stock, $.01 Par Value | 647 | $0.00 | $0.00 |
DisclosureSEC source: 0001240679-17-000028 · edgar.xml · nonDerivative · entry 1 FELDMANN CYNTHIA L · CIK 0001264554 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 647 F1 · shares: Represents shares issued under the issuer's 2009 Non-Employee Director Stock Incentive Plan Read SEC document |
| May 19, 2017 Filed May 23, 2017 17:55 UTC | HANGER, INC. HGR · Entity 14115 | GrantCommon Stock | 10,964 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-17-022016 · doc1.xml · nonDerivative · entry 1 FELDMANN CYNTHIA L · CIK 0001264554 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 109,072 F1 · shares: Consists of shares of restricted stock granted under the Company's 2016 Omnibus Incentive Plan (the "Plan"), which vest 100% on May 19, 2018, subject to certain provisions of the Plan. Read SEC document |
| May 10, 2017 Filed May 12, 2017 20:35 UTC | STERIS plc STE · Entity 158792 | SaleOrdinary Shares, 10 pence par value | 2,500 | $76.25 | $190,625.00 |
DisclosureSEC source: 0001209191-17-031979 · doc4.xml · nonDerivative · entry 1 FELDMANN CYNTHIA L · CIK 0001264554 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,337 F1 · price: This represents the average sales price of the 2,500 shares sold in the open market. The actual sales prices ranged from $76.24 per share to $76.27 per share. The Reporting Person, upon request by the SEC staff, will provide full information regarding the number of shares sold at each of the separate sales prices. Read SEC document |
| November 04, 2016 Filed Nov 7, 2016 21:41 UTC | STERIS plc STE · Entity 158792 | SaleOrdinary Shares, 0.10 par value | 2,000 | $65.43 | $130,867.00 |
DisclosureSEC source: 0001209191-16-148643 · doc4.xml · nonDerivative · entry 3 FELDMANN CYNTHIA L · CIK 0001264554 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,837 Read SEC document |
| November 03, 2016 Filed Nov 7, 2016 21:41 UTC | STERIS plc STE · Entity 158792 | Exercise / conversionDirector Stock Option (right to buy) · Derivative | 2,744 | $0.00 Strike: $34.17 | $0.00 |
DisclosureSEC source: 0001209191-16-148643 · doc4.xml · derivative · entry 4 FELDMANN CYNTHIA L · CIK 0001264554 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares, 0.10 par value · 2,744 shares Expires 2018-07-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: This option to purchase 2,744 New STERIS ordinary shares, which is fully vested, was received in the merger in exchange for an option to purchase 2,744 STERIS common shares for $34.17 per share, subject to the same terms and conditions as the original STERIS stock option. Read SEC document |
| November 03, 2016 Filed Nov 7, 2016 21:41 UTC | STERIS plc STE · Entity 158792 | SaleOrdinary Shares, 0.10 par value | 2,744 | $64.66 | $177,417.98 |
DisclosureSEC source: 0001209191-16-148643 · doc4.xml · nonDerivative · entry 2 FELDMANN CYNTHIA L · CIK 0001264554 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,837 F1 · price: Price reflects a weighted average sale price for multiple transactions ranging from $64.64 to $64.6580 per share, inclusive. The Reporting Person undertakes to provide, upon request by the SEC Staff, the Issuer or a security holder of the Issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| November 03, 2016 Filed Nov 7, 2016 21:41 UTC | STERIS plc STE · Entity 158792 | Exercise / conversionOrdinary Shares, 0.10 par value | 2,744 | $34.17 | $93,762.48 |
DisclosureSEC source: 0001209191-16-148643 · doc4.xml · nonDerivative · entry 1 FELDMANN CYNTHIA L · CIK 0001264554 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,581 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.